// Nadia Cambados 1 , Thomas Walther 2, 4, 5 , Karen Nahmod 6 , Johanna M. Tocci 1 , Natalia Rubinstein 1, 7 , Ilka Bohme 2, 3 , Marina Simian 8 , Rocio Sampayo 8 , Melisa Del Valle Suberbordes 1 , Edith C. Kordon 1, 9 and Carolina Schere-Levy 1 1 Instituto de Fisiologia, Biologia Molecular y Neurociencias, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires, Argentina 2 Department of Obstetrics, University of Leipzig, Leipzig, Germany 3 Department of Pediatric Surgery, University of Leipzig, Leipzig, Germany 4 Department Pharmacology and Therapeutics, School of Medicine and School of Pharmacy, University College Cork, Cork, Ireland 5 Institute of Medical Biochemistry and Molecular Biology, University Medicine Greifswald, Greifswald, Germany 6 Department of Pediatrics, Immunology, Allergy and Rheumatology, Center for Human Immunobiology, Texas Children’s Hospital, Houston, Texas, USA 7 Departamento de Fisiologia, Biologia Molecular y Celular, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires, Argentina 8 Instituto de Nanosistemas, Universidad Nacional de San Martin, Buenos Aires, Argentina 9 Departmento de Quimica Biologica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires, Argentina Correspondence to: Carolina Schere-Levy, email: carolinaschere@gmail.com Keywords: AKT, angiotensin II, angiotensin-(1-7), breast cancer cells, epithelial–mesenchymal transition Received: November 04, 2016 Accepted: June 02, 2017 Published: July 17, 2017 ABSTRACT Angiotensin (Ang) II, the main effector peptide of the renin-angiotensin system, has been implicated in multiple aspects of cancer progression such as proliferation, migration, invasion, angiogenesis and metastasis. Ang-(1-7), is a biologically active heptapeptide, generated predominantly from AngII by the enzymatic activity of angiotensin converting enzyme 2. Previous studies have shown that Ang-(1-7) counterbalances AngII actions in different pathophysiological settings. In this study, we have analysed the impact of Ang-(1-7) on AngII-induced pro-tumorigenic features on normal murine mammary epithelial cells NMuMG and breast cancer cells MDA-MB-231. AngII stimulated the activation of the survival factor AKT in NMuMG cells mainly through the AT1 receptor. This PI3K/AKT pathway activation also promoted epithelial–mesenchymal transition (EMT). Concomitant treatment of NMuMG cells with AngII and Ang-(1-7) completely abolished EMT features induced by AngII. Furthermore, Ang-(1-7) abrogated AngII induced migration and invasion of the MDA-MB-231 cells as well as pro-angiogenic events such as the stimulation of MMP-9 activity and VEGF expression. Together, these results demonstrate for the first time that Ang-(1-7) counteracts tumor aggressive signals stimulated by AngII in breast cancer cells emerging the peptide as a potential therapy to prevent breast cancer progression.